EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY-NC 4.0

Prevalence and determinants of dolutegravir resistance among people living with HIV with virologic failure in North-Eastern Uganda: a retrospective cross-sectional study (2022–2024)

Saadick Mugerwa Ssentongo iD, Hamidah Kakooza Mulungi, Ronald Opito, William Okello, Connie Nait, Ivan Katende, Baker Bakashaba, Bonniface Oryokot

Therapeutic Advances in Infectious Disease · 2026-08 · 13

DOI: 10.1177/20499361261467152 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Therapeutic Advances in Infectious Disease, online erschienen am 01.08.2026. Verfasst von Saadick Mugerwa Ssentongo und 7 weiteren Autor:innen. Beteiligte Einrichtung: AIDS Information Centre (AIC), Directorate of Program Management and Capacity Development, Kampala, Uganda. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In 2016, Uganda adopted the WHO HIV drug resistance (HIVDR) monitoring strategy to track treatment outcomes following the introduction of a dolutegravir (DTG) based regimen as first line among people living with HIV (PLHIV). However, despite widespread transition to DTG-based regimens, evidence on acquired DTG resistance and its determinants remains limited.

Objectives

To determine the prevalence of acquired DTG resistance among PLHIV with virologic failure and identify associated factors in North-Eastern Uganda.

Design

We conducted a retrospective cross-sectional study from 24 accredited antiretroviral therapy health facilities in North-Eastern Uganda by 28th February 2025.

Methods

The study included eligible PLHIV on DTG-based regimens with at least 2 viral loads >1000 copies/mL and a documented HIV genotypic resistance testing result between April 2022 and July 2024. Clinical data were extracted from the national drug resistance dashboard and verified against facility electronic medical records. Logistic regression via generalised estimating equations (GEE) was used to identify factors associated with DTG resistance. A p -value < 0.05 was considered statistically significant.

Results

Of 225 participants, the median age was 19 years (interquartile range: 15–39), and 55.1% ( n = 124) were male. The prevalence of high-level to intermediate DTG resistance was 18.7% ( n = 42), with 14.2% ( n = 32) having high-level resistance to DTG and 4.4% ( n = 10) intermediate resistance. Most participants were unemployed (60.0%, n = 135) and had not disclosed their HIV status (74.2%, n = 167). DTG resistance was associated with presence of nucleoside reverse transcriptase inhibitor (NRTI) drug resistance mutations (DRMs) (adjusted odds ratio (aOR); 12.14, 95% confidence interval (CI): 4.14–35.65, p < 0.001), poor adherence (aOR; 6.19, 95% CI: 2.54–15.11, p = 0.001), DTG use ⩾ 3 years (aOR; 9.19, 95% CI: 1.60–52.74, p = 0.013), and alcohol/substance abuse (aOR; 3.94, 95% CI: 1.74–8.91, p = 0.001).

Conclusion

Nearly one in five PLHIV with virologic failure exhibited DTG resistance, predominantly high-level. Key associated factors included poor adherence, being on DTG for ⩾3 years, alcohol/substance abuse, and the presence of relevant NRTI DRM. Strengthening family and peer support, integrating substance abuse screening and management in HIV care, and improving adherence may help reduce the risk of DTG resistance. These findings highlight the urgent need for enhanced HIVDR monitoring and tailored interventions to sustain progress toward HIV epidemic control by 2030.

Schlagwörter

Stichwörter der Autor:innen

Ugandaantiretroviral therapydolutegravir resistancepeople living with HIVvirologic failure

Autor:innen und Institutionen

  • AIDS Information Centre (AIC), Directorate of Program Management and Capacity Development, Kampala, Uganda.
  • Mbarara National Referral Hospital, Ministry of Health, Mbarara City, Uganda.
  • Soroti Regional Referral Hospital, Ministry of Health, Soroti City, Uganda.

ORCID-Profile: Saadick Mugerwa Ssentongo

Zitieren

APA

Mugerwa Ssentongo, S., Kakooza Mulungi, H., Opito, R., Okello, W., Nait, C., Katende, I., Bakashaba, B., & Oryokot, B. (2026). Prevalence and determinants of dolutegravir resistance among people living with HIV with virologic failure in North-Eastern Uganda: a retrospective cross-sectional study (2022–2024). Therapeutic Advances in Infectious Disease, 13. https://doi.org/10.1177/20499361261467152

Vancouver

Mugerwa Ssentongo S, Kakooza Mulungi H, Opito R, Okello W, Nait C, Katende I, et al. Prevalence and determinants of dolutegravir resistance among people living with HIV with virologic failure in North-Eastern Uganda: a retrospective cross-sectional study (2022–2024). Therapeutic Advances in Infectious Disease. 2026;13. doi:10.1177/20499361261467152

BibTeX
@article{MugerwaSsentongo2026,
  author = {Mugerwa Ssentongo, Saadick and Kakooza Mulungi, Hamidah and Opito, Ronald and Okello, William and Nait, Connie and Katende, Ivan and Bakashaba, Baker and Oryokot, Bonniface},
  title = {Prevalence and determinants of dolutegravir resistance among people living with HIV with virologic failure in North-Eastern Uganda: a retrospective cross-sectional study (2022–2024)},
  journal = {Therapeutic Advances in Infectious Disease},
  year = {2026},
  volume = {13},
  doi = {10.1177/20499361261467152}
}
Kostenlos starten →